With 0.86 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.03 million shares. During the session, the Healthcare Plans company that operates in wider Healthcare sector, reached to the highest price of $268.91 whereas the lowest price it dropped to was $260.45. The 52-week range on HUM shows that it touched its highest point at $464.38 and its lowest point at $213.31 during that stretch. It currently has a 1-year price target of $283.76. With its current market cap of 32.29 billion, HUM has annualized dividend of $3.54 while the current yield stands at 1.32%. Beta for the stock currently stands at 0.55.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HUM was up-trending over the past week, with a rise of 5.68%, but this was down by -4.83% over a month. Three-month performance surged to 10.25% while six-month performance fell -29.29%. The stock lost -41.80% in the past year, while it has gained 5.68% so far this year. A look at the trailing 12-month EPS for HUM yields 11.29 with Next year EPS estimates of 16.88. For the next quarter, that number is -2.17. This implies an EPS growth rate of -38.09% for this year and 4.51% for next year. EPS is expected to grow by 2.51% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 10.46%.
Float and Shares Shorts:
At present, 120.41 million HUM shares are outstanding with a float of 120.14 million shares on hand for trading. On 2024-12-13, short shares totaled 4.45 million, which was 370.0 higher than short shares on 1731628800. In addition to Ms. Susan Marie Diamond as the firm’s Chief Financial Officer, Mr. Joseph C. Ventura serves as its Chief Legal Officer.
Institutional Ownership:
Through their ownership of 0.94628 of HUM’s outstanding shares, institutional investors have minority control over the company.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HUM since 18 analysts follow the stock currently. There are 11 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 7 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With HUM analysts setting a high price target of 425.0 and a low target of 248.0, the average target price over the next 12 months is 296.09546. Based on these targets, HUM could surge 58.51% to reach the target high and fall by -7.51% to reach the target low. Reaching the average price target will result in a growth of 10.43% from current levels.
Analysts have provided yearly estimates in a range of $16.40209 being high and $15.8617 being low. For HUM, this leads to a yearly average estimate of $16.15191. Based on analyst estimates, the high estimate for the next quarter is $7.87 and the low estimate is $5.12. The average estimate for the next quarter is thus $6.97.
